Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure

Cardiovascular Research

Volumn 53, Issue 4, 2002, Pages 963-970

  Ding, Shuang Shuang ^a,b   Qiu, Changbin ^a,b   Hess, Patrick ^a   Xi, Jian Fei ^a,b   Clozel, Jean Paul ^a   Clozel, Martine ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Endothelins; Heart failure; Infarction; Renal function; Vasoactive agents

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOSE RESPONSE; DRUG EFFECT; GLOMERULUS FILTRATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART WEIGHT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SODIUM RETENTION; SODIUM URINE LEVEL; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL INFARCTION; NATRIURESIS; RATS; RATS, WISTAR; RECEPTORS, ENDOTHELIN; RENAL CIRCULATION; SULFONAMIDES; VASOCONSTRICTION;

EID: 0036196807     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00558-2     Document Type: Article

References (42)

1. Renal hemodynamics in heart disease
2. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
3. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways
4. Endothelin: A potent renal and systemic vasoconstrictor peptide
5. Endothelin has biological actions at pathophysiological concentrations
6. Endothelin in experimental congestive heart failure in the anesthetized dog
7. Contribution of the endothelin system to the renal hypoperfusion associated with experimental congestive heart failure
8. Activation of cardiorenal and pulmonary tissue endothelin-1 in experimental heart failure
9. Bosentan improves renal regional blood flow in rats with experimental congestive heart failure
10. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use
11. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure
12. Chronic oral endothelin type A receptor antagonism in experimental heart failure
13. Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252
14. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
15. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
16. Eine einfache colorimetrische methode zur inulinbestimmung für nieren clearance untersuchungen bei stoffwechselgesunden und diabetikern
17. Simplification of the anthrone method for the determination of inulin in clearance studies
18. The renal clearances of substituted hippuric acid derivates and other aromatic acids in dogs and man
19. Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney
20. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade
21. Angiotensin II and α 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension
22. Role of angiotensin. II. In the altered renal function of congestive heart failure
23. Intrarenal hemodynamics in low- and high-output cardiac failure in rats
24. Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction
25. Effects of α1-adrenergic blockade on intrarenal hemodynamics in heart failure rats
26. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist RO 47-0203 (bosentan)
27. Endothelin antagonism with bosentan: A review of potential applications
28. Endothelin in chronic heart failure: Current position and future prospects
29. Endothelins in the normal and diseased kidney
30. Mechanisms and receptor subtypes involved in the stimulatory action of endothelin-1 on rat adrenal zona glomerulosa
31. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothelin A receptor antagonism
32. Role of endothelin in acute renal failure due to rhabdomyolysis in rats
33. Endothelin and angiotensin mediate most glomerular responses to nitric oxide inhibition
34. Regression of renal vascular fibrosis by endothelin receptor antagonism
35. Phosphoinositide-generated messengers in cardiac signal transduction
36. Role for endothelin-1 in angiotensin II-mediated hypertension
37. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade
38. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure
39. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: Effects on left ventricular performance
40. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
41. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure
42. Hemodynamic effect of endothelin antagonists in dogs with myocardial infarction